What is the difference between cagrilintide monotherapy and the CagriSema combination?

Name: Cagrilintide
Price: 80 USD
Availability: InStock

Cagrilintide as monotherapy produced modest weight reductions of approximately 10% in phase 2 studies. The CagriSema combination (cagrilintide 2.4mg + semaglutide 2.4mg) showed additive effects with phase 2 data reporting over 15% weight reduction, suggesting complementary mechanisms between amylin and GLP-1 receptor pathways.

New

Cagrilintide

Long-acting amylin receptor agonist with a 7-day half-life. Studied for weight management both as monotherapy and in combination with semaglutide (CagriSema).

Fat LossGH Boost

● In Stock

Select Variant

Quantity (vials)

Buy more, save more

—

1+ vials

−5%

3+ vials

−10%

5+ vials

−20%

10+ vials

Total Price

$80

For research & laboratory use only. Not for human consumption.

Half-Life

7 days

Administration Route

Subcutaneous injection

Amylin Receptor Agonist

Mimics satiety hormone to suppress appetite centrally

Slows Gastric Emptying

Extends post-meal fullness via hypothalamic pathways

Synergistic with GLP-1

Combined with semaglutide (CagriSema) shows 15.6% loss

Effect Profile

Based on primary research mechanisms

Fat Loss

Hunger Control

Metabolic Health

Energy

Mechanism of Action

Cagrilintide is a fatty acid-conjugated analog of human amylin (islet amyloid polypeptide, IAPP) with high affinity for amylin receptors (AMY1-3). Amylin receptors are expressed in the area postrema and nucleus tractus solitarius of the brainstem, mediating satiety, slowing gastric emptying, and suppressing post-prandial glucagon. The fatty acid side chain enables once-weekly dosing by extending the half-life to approximately 7 days.